Study identifier:BY9010/IT-101
ClinicalTrials.gov identifier:NCT00163319
EudraCT identifier:N/A
CTIS identifier:N/A
Comparison of inhaled ciclesonide (640 mcg/day) and fluticasone propionate (1000 mcg/day) in patients with moderate and severe persistent asthma
asthma
Phase 3
No
Ciclesonide
All
500
Interventional
18 Years - 75 Years
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Sept 2016 by AstraZeneca
AstraZeneca
-
The aim of the study is to compare the safety and efficacy of ciclesonide versus fluticasone propionate on the lung function, symptoms, use of rescue medication, and occurrence of side effects (such as candidiasis, hoarseness) in adults with persistent asthma. Ciclesonide will be inhaled twice daily at one dose level; fluticasone propionate will be inhaled twice daily at one dose level. The study duration consists of a baseline period (2 weeks) and a treatment period (24 weeks). The study will provide further data on safety and tolerability of ciclesonide.
Location
Location
Bruxelles, Belgium, 1000
Location
Bruxelles, Belgium, 1040
Location
Jette, Belgium, 1090
Location
Bruxelles, Belgium, 1190
Location
Turnhout, Belgium, 2300
Location
Halen, Belgium, 3545
Location
Namur, Belgium, 5000
Location
Maison-Saint-Gérard, Belgium, 5640
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.